United Therapeutics Corp. has reached an agreement with an Israeli regenerative medicine company to develop and commercialize 3D-bioprinted lungs for transplants.
The deal gives the Silver Spring biotech’s organ manufacturing and transplantation subsidiary, Lung Biotechnology PBC, an exclusive license to Israel-based CollPlant’s proprietary recombinant human collagen (rhCollagen) products, as well as its BioInk technology used in the 3D bioprinting of tissues and organs.
United Therapeutics said it will pay $5 million upfront with subsequent milestone payments of up to $15 million. The local drugmaker also has the option to expand the license to include up to three more organs beyond lungs — which would translate to payments of up to $9 million and additional developmental milestone payments of up to $15 million. CollPlant is also entitled to royalties on sales for products covered by its patents.
Under the deal, CollPlant will manufacture and supply BioInk for a few years. United…Read the full story from the Washington Business Journal.